Form 4: IRADIMED Director Hawkins Receives RSU Grant

IRADIMED Corporation's Director, James B. Hawkins, was granted 1,026 restricted stock units under the company's 2023 Equity Incentive Plan.

Summary

• Director James B. Hawkins of IRADIMED Corporation (IRMD) received a grant of 1,026 Restricted Stock Units (RSUs).
• The grant was made on December 11, 2025, under the company's 2023 Equity Incentive Plan.
• These RSUs will convert into common stock on a one-for-one basis upon vesting.
• The RSUs vest in two equal annual installments, commencing on December 11, 2026.
• Following this transaction, Mr. Hawkins beneficially owns 1,932 derivative securities.

Sentiment

Score: 6

Explanation: A routine insider transaction (equity grant) for a director, which is generally a positive sign of alignment but not a significant market moving event on its own. It reflects standard corporate governance and compensation practices.

Positives

• The grant of Restricted Stock Units to Director James B. Hawkins aligns his interests with those of shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for retaining and motivating key personnel and directors.

Future Outlook

The granted Restricted Stock Units are scheduled to vest in two equal annual installments, beginning on December 11, 2026, indicating future equity distribution to the director.

Management Comments

• On December 11, 2025, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan.
• The restricted stock units vest in two equal annual installments beginning on December 11, 2026.

Industry Context

The grant of restricted stock units to a director is a common practice in publicly traded companies across various industries, including healthcare technology, to attract, retain, and incentivize board members by aligning their financial interests with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for director compensation is a widely accepted practice, comparable to compensation structures at companies like Medtronic (MDT) or Stryker (SYK), which frequently utilize equity awards to incentivize their non-employee directors.
• The vesting schedule, typically over several years, is standard for promoting long-term commitment, similar to equity plans observed at many S&P 500 companies.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to Director James B. Hawkins constitutes a related party transaction, as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making. It also represents a minor dilution risk upon vesting, though this is standard for equity compensation.
• Director (James B. Hawkins): Receives equity compensation, increasing his stake and financial incentive in the company's performance.

Next Steps

• The Restricted Stock Units will vest in two equal annual installments starting December 11, 2026.
• Upon vesting, the reporting person will receive shares of common stock.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a standard compensation practice and does not provide new information that would significantly alter the fundamental investment thesis for IRADIMED. It indicates ongoing alignment of director interests with shareholders but is not a catalyst for a "buy" or "sell" recommendation. Therefore, a "hold" recommendation is appropriate as it maintains the current position based on existing company fundamentals.

Keywords

IRADIMED, IRMD, Form 4, Restricted Stock Units, RSU, Equity Incentive Plan, Director Compensation, Insider Transaction, Stock Grant, Beneficial Ownership